Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8207125 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Apr, 2025
(11 months from now) | |
US7232818 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Apr, 2025
(11 months from now) | |
US8207297 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Apr, 2025
(11 months from now) | |
US7417042 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Jul, 2026
(2 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8207126 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Apr, 2025
(11 months from now) | |
US7491704 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Apr, 2025
(11 months from now) | |
US8129346 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Apr, 2025
(11 months from now) | |
US8207127 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Apr, 2025
(11 months from now) | |
US7737112 | ONYX PHARMS AMGEN | Composition for enzyme inhibition |
Dec, 2027
(3 years from now) | |
USRE47954 | ONYX PHARMS AMGEN | Combination therapy with peptide epoxyketones |
Oct, 2029
(5 years from now) | |
US9511109 | ONYX PHARMS AMGEN | Combination therapy with peptide epoxyketones |
Oct, 2029
(5 years from now) | |
US9493582 | ONYX PHARMS AMGEN | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(8 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-712) | Jul 24, 2018 |
New Indication(I-722) | Jan 21, 2019 |
New Indication(I-723) | Jan 21, 2019 |
New Chemical Entity Exclusivity(NCE) | Jul 20, 2017 |
Orphan Drug Exclusivity(ODE) | Jul 20, 2019 |
New Dosing Schedule(D-172) | Sep 28, 2021 |
Orphan Drug Exclusivity(ODE-27) | Jul 20, 2019 |
New Indication(I-842) | Aug 20, 2023 |
NCE-1 date: 20 July, 2016
Market Authorisation Date: 07 June, 2018
Treatment: Kyprolis is indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy; Use in combination with lenalidomide ...
Dosage: POWDER;INTRAVENOUS